echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Drugs Articles > The mRNA vaccine giant will launch 34 vaccine projects

    The mRNA vaccine giant will launch 34 vaccine projects

    • Last Update: 2022-09-21
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    As we all know, As an mRNA vaccine giant, Moderna has total revenue of $18.


    Among them, the new crown vaccine Spikevax (mRNA-1273) sold more than 800 million doses in 2021 and generated revenue of $


    Moderna's R&D pipeline spans a variety of areas, including COVID-19 vaccines, influenza vaccines, preventive vaccines, system secretion and cell surface therapy; Exploratory areas include tumor vaccines, local regenerative therapies, and cell therapies


    COVID-19 Vaccine Flu Vaccine Tumor Vaccine

    In 2023-2026, Moderna expects to launch a variety of vaccines worldwide, including human respiratory syncytial virus (RSV) vaccines and influenza vaccines, COVID-19 vaccines, and mRNA vaccines


    Influenza vaccine mRNA-1010

    On Thursday, Moderna showcased the company's clinical programs for multiple indications, including 34 vaccines under development


    34 vaccine projects

    Moderna said it will continue to invest in its manufacturing capacity to support vaccine production


    1 Rare disease

    1 Rare disease

    Because of the potential of mRNA technology, Moderna will use it for rare disease research


    For propionic acidemia (PA), the company is developing a drug, mRNA-3927, that encodes the key enzyme that patients are missing, propionyl-CoA carboxylase, thereby alleviating metabolic abnormalities


    mRNA-3927

    For methylmalonic acidemia (MMA), the company has included the first two groups of patients in phase I/II studies to evaluate the safety and pharmacology


    mRNA-3705

    For glycogen storage disease type I.


    mRNA-3745

    Moderna is also advancing a new drug candidate, mRNA-3139, for the treatment


    mRNA-3139

    2 Respiratory vaccines

    2 Respiratory vaccines

    Moderna's COVID-19 vaccine has been a huge success


    Moderna has introduced two COVID-19 vaccine enhancers to meet different market needs: mRNA-1273.


    mRNA-1273.


    mRNA-1273.


    The company's influenza vaccine candidate, mRNA-1010, is in phase III clinical development in the southern hemisphere, with approximately 6,000 patients involved


    mRNA-1010

    There is currently no mature RSV vaccine
    for clinical application.
    In Respiratory Syncytial Virus (RSV), Moderna initiated a Phase III trial that will evaluate the efficacy of mRNA-1345 in older people aged 60 years and older
    .
    To date, the test has recruited more than 24,000 patients
    .
    34,000 patients are expected to participate in the trial
    .
    In addition to the elderly, RSV is also a virus
    of concern to young children.
    Moderna also conducted a Phase I trial in children to assess the effects
    of mRNA-1345.

    mRNA-1345

    In addition to the single-dose vaccine, Moderna is advancing several respiratory infection bacterial combination vaccines, including a Phase I/II trial on mRNA-1073 to test its effects on
    COVID-19 and influenza.
    The company is also working on mRNA-1230, a candidate vaccine for COVID-19, influenza and RSV, and is expected to launch clinical trials
    this year.

    mRNA-1073

    3 CMV and cancer vaccines

    3CMV and cancer vaccines

    Moderna is developing a cytomegalovirus (CMV) vaccine, and the company is evaluating a phase III trial of mRNA-1647 designed to prevent congenital CMV, and recruitment for this study is ongoing
    .

    mRNA-1647

    Moderna is also developing personalized cancer vaccines, including mRNA-4157, which are used in conjunction with Merck's Keytruda for trial evaluation
    in patients with resected melanoma at high risk of recurrence.
    The combination therapy study is still in Phase II clinical trials and is expected to receive first-hand data
    by the end of the fourth quarter of this year.

    mRNA-4157

    It seems that Moderna's mRNA vaccine is not only limited to the new crown, but can even be used in the
    treatment of tumors and various diseases.

    Resources:

    Resources:

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.